Delivery Order SPE2DB22D3011-SPE2DB25FP8LF

Award Date 1/7/25
Potential Completion Date 1/29/25
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,960.30, is a delivery order for the provision of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has an ultimate completion date of July 2, 2024 and does not have a set-aside designation, indicating open competition. Additionally, AmerisourceBergen holds a significant...
This federal contract award, valued at $13,408.24, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a specialty pharmaceutical product, with a period of performance through January 22, 2025. The contract is a firm-fixed-price Delivery Order and does not have a set-aside designation. In addition to this specific contract,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The $12,960.30 firm-fixed price delivery order is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a specialty medication. The award has an ultimate completion date of November 25, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,408.24 firm fixed-price delivery order is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product. The contract has a period of performance through February 18, 2025 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite...
This federal contract award, valued at $12,960.30, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of VYNDAMAX 61 MG CAPSULE UD 30S, a pharmaceutical product, with a completion date of June 5, 2024. This award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the drug VYNDAMAX 61 MG CAPSULE UD 30S. The $12,960.30 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) on June 25, 2024, with a completion date of July 17, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,408.24 Firm Fixed Price Delivery Order is for the provision of VYNDAMAX 61 MG CAPSULE UD 30S, a specialty medication. The contract has an ultimate completion date of January 10, 2025 and was awarded on December 18, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $12,960.30 firm-fixed-price delivery order contract is for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, a medication. The contract has an ultimate completion date of July 10, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,690.70 firm fixed-price delivery order is for the supply of VYNDAMAX 61 MG Capsules, with a completion date of July 27, 2022. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $12,960.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of VYNDAMAX 61 MG CAPSULE UD 30S, with an ultimate completion date of August 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB25FP8LF
    Delivery Order

This federal contract award, valued at $13,408.24, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for VYNDAMAX 61 MG CAPSULE UD 30S, with a completion date of January 29, 2025. This contract is not designated as a set-aside and represents an open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. In addition, the company maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

Generated 4/8/25, 9:48 AM